Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2013

Filed with the SEC on Aug 6, 2013 and accepted by EDGAR at Aug 6, 2013, 10:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-04-01 to 2013-06-30$97.0kus-gaap:Revenues
Revenue6 months2013-01-01 to 2013-06-30$2.5mus-gaap:Revenues
Research and development3 months2013-04-01 to 2013-06-30$15.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2013-01-01 to 2013-06-30$29.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-04-01 to 2013-06-30−$18.7mus-gaap:OperatingIncomeLoss
Operating income6 months2013-01-01 to 2013-06-30−$36.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-04-01 to 2013-06-30$519.0kus-gaap:InterestExpense
Interest expense6 months2013-01-01 to 2013-06-30$829.0kus-gaap:InterestExpense
Net income3 months2013-04-01 to 2013-06-30−$19.0mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income6 months2013-01-01 to 2013-06-30−$36.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2013-04-01 to 2013-06-30−$0.24us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2013-01-01 to 2013-06-30−$0.47us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2013-01-01 to 2013-06-30−$35.3mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2013-01-01 to 2013-06-30$917.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-06-30$25.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-06-30$156.4mus-gaap:AssetsCurrent
Total assetsAt period end2013-06-30$196.2mus-gaap:Assets
Current liabilitiesAt period end2013-06-30$12.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-06-30$19.1mus-gaap:Liabilities
Shareholders' equityAt period end2013-06-30$177.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-13-060226. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.